^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2R agonist

    Related drugs:
    1d
    Therapy of melanoma : Current standards and future perspectives (PubMed, Pathologie (Heidelb))
    Multimodal treatment strategies have fundamentally improved the prognosis of melanoma. Therapy selection should be individualized based on molecular markers and disease stage. Future developments aim to integrate combination strategies, personalized immunotherapeutic approaches, and the overcoming of resistance mechanisms.
    Review • Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3)
    |
    BRAF mutation • BRAF V600
    |
    Nidlegy (darleukin/fibromun)
    17d
    L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P2, N=180, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting | Initiation date: Feb 2026 --> Jun 2026
    Enrollment open • Trial initiation date
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    2ms
    L19IL2/TNF in Patients With Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    Nidlegy (darleukin/fibromun)
    2ms
    An open-label, dose-escalation and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of combination therapy with LAT010 plus pembrolizumab in patients with locally advanced or metastatic solid tumors (ChiCTR2600121542)
    P=N/A, N=27, Shanxi Bethune Hospital; Shanxi Bethune Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation
    |
    Keytruda (pembrolizumab)
    3ms
    Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus (clinicaltrials.gov)
    P2, N=66, Recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not yet recruiting --> Recruiting | Trial completion date: May 2029 --> May 2028 | Initiation date: Nov 2025 --> Mar 2026
    Enrollment open • Trial completion date • Trial initiation date
    4ms
    A Phase II Study of ILKN421H With Pembrolizumab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, iLeukon Therapeutics, Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    4ms
    PH-ICKPD1-02/21: A phase 2 study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 Pembrolizumab, in stage III/IV unresectable melanoma patients with resistance to anti-PD1 checkpoint inhibitors (INTACT / MeRCI) (2024-519326-20-00)
    P1/2, N=65, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    4ms
    L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma (2025-523231-19-00)
    P1/2, N=54, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    4ms
    L19IL2/TNF in patients with basal cell carcinoma (2025-523230-77-00)
    P1/2, N=53, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    4ms
    PHL19IL2TNFCOMB04/24: L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) (2025-523229-16-00)
    P1/2, N=85, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    6ms
    Neo-DREAM: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (clinicaltrials.gov)
    P3, N=186, Recruiting, Philogen S.p.A. | Trial completion date: Jun 2026 --> Dec 2031 | Trial primary completion date: Jun 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Nidlegy (darleukin/fibromun)
    7ms
    A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=189, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Oct 2025 | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)